Frank Yocca, Chief Scientific Officer at BioXcel Therapeutics, Inc. (BTAI), bought 500 shares at $5.02 ($3K) on 2018-11-29, disclosed to the SEC on 2018-11-30.
Open-market purchase of $3k BTAI by Chief Scientific Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| Filing → |
| BTAI | SELL | 2024-10-03 | $4K | — | Filing → |
| BTAI | SELL | 2024-09-17 | $245 | — | Filing → |
| BTAI | SELL | 2024-06-18 | $476 | — | Filing → |